Myotonic dystrophy is a hereditary neuromuscular disorder characterized by delayed muscle relaxation (myotonia) and multi‑system involvement. It affects roughly 10 cases per 100,000 in the general population. According to the myotonic dystrophy drug pipeline by Expert Market Research, there are over 20 companies actively developing more than 22 pipeline therapies, spanning small molecules, gene therapies, oligonucleotides, and drug‑repurposing approaches. Key candidates include mexiletine, tideglusib, and pitolisant. The growing focus on precision RNA‑based interventions, increasing clinical trial activity, and orphan drug incentives are expected to drive significant market growth in the coming years.
Major companies involved in the myotonic dystrophy pipeline analysis include Avidity Biosciences, Inc., Sanofi, and others.
Leading drugs currently in the pipeline include AOC 1001, SAR446268, VX-670, and others.
The myotonic dystrophy treatment pipeline is expanding due to increasing gene therapy and antisense oligonucleotide developments, rising clinical trials, and growing investments in rare neuromuscular disorder therapeutics.
The Myotonic Dystrophy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into myotonic dystrophy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for myotonic dystrophy. The myotonic dystrophy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The myotonic dystrophy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with myotonic dystrophy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to myotonic dystrophy.
Read more about this report - Request a Free Sample
Myotonic dystrophy is a rare, progressive genetic disorder affecting skeletal, cardiac, and smooth muscles. It occurs due to an abnormal trinucleotide expansion in the DMPK gene, leading to toxic RNA accumulation, altered protein splicing, myotonia, and progressive muscle weakness, impacting mobility, heart function, breathing, and cognition.
Myotonic dystrophy treatments focus on managing symptoms and slowing progression, including investigational therapies like antisense oligonucleotides, physical therapy, cardiac care, and respiratory support to improve quality of life. In January 2025, Dyne Therapeutics’ DYNE-101, granted FDA Fast Track designation, is a promising antisense oligonucleotide therapy targeting toxic DMPK RNA to correct spliceopathy, currently in Phase 1/2 ACHIEVE trials with potential accelerated U.S. approval in H1 2026.
According to Merck & Co., Inc., myotonic dystrophy (MD) affects approximately 10 cases per 100,000 individuals globally. As per Thomas D. Bird et al., 2024, myotonic dystrophy type 1 (DM1) prevalence ranges from 1:100,000 in parts of Japan to 1:10,000 in Iceland, with a worldwide average of 1:20,000. A 2021 New York State newborn screening found that 4.76 per 10,000 newborns had dystrophia myotonica-protein kinase (DMPK) cytosine-thymine-guanine (CTG) expansions of 50 repeats or more, while 19.1 per 10,000 had premutations of 35–49 repeats. According to Susmit Kosta et al., 2025, prevalence in India is approximately 1 in 20,000, with regional variations. The Centers for Disease Control and Prevention (CDC) notes that Duchenne/Becker muscular dystrophy (DMD/BMD) affects around 14 per 100,000 males aged 5–24 years. These findings highlight the ongoing need for targeted therapies in the Myotonic Dystrophy drug development pipeline.
This section of the report covers the analysis of myotonic dystrophy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The myotonic dystrophy pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 41%, covers a major share of the total myotonic dystrophy clinical trials. Phase I holds 32% and phase III accounts for 27%. This positive distribution signals a strong mid‑stage momentum, potentially accelerating treatments and expanding market opportunities in the myotonic dystrophy therapeutic landscape.
The drug molecule categories covered under the myotonic dystrophy pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The myotonic dystrophy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for myotonic dystrophy. Gene and protein-based therapies are emerging in the myotonic dystrophy drug pipeline to target underlying disease mechanisms. For instance, JUV-161, an engineered biologic containing IGF-2 protein for subcutaneous administration, is under clinical investigation. In January 2024, the U.S. Food and Drug Administration granted it orphan drug designation to support its development and address unmet patient needs.
The EMR report for the myotonic dystrophy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed myotonic dystrophy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in myotonic dystrophy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for myotonic dystrophy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of myotonic dystrophy drug candidates.
Del-desiran, developed by Avidity Biosciences, Inc., is a next-generation therapeutic designed to target the root cause of myotonic dystrophy type 1 (DM1). It consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1) and is conjugated with siRNA to selectively degrade DMPK mRNA. Preclinical studies show it delivers siRNA efficiently to skeletal, cardiac, and smooth muscles, producing durable, dose-dependent reductions in disease-related RNA. Currently, it is advancing through a global Phase 3 trial to assess its efficacy and safety in patients with DM1. The study is examining the drug’s impact on muscle function and overall disease progression over a 54-week treatment period, with participants receiving doses every eight weeks.
SAR446268 is an investigational adeno-associated viral vector-mediated gene therapy sponsored by Sanofi, currently being evaluated in a Phase 1/Phase 2 study for participants aged 10 to 50 years with non-congenital myotonic dystrophy type 1 (DM1). The study is examining the safety, tolerability, and efficacy of a single intravenous administration in reducing DMPK mRNA levels and improving neuromuscular function. SAR446268 uses a vectorized RNA interference (RNAi) mechanism to silence toxic DMPK transcripts, eliminating RNA foci that disrupt muscle splicing, thereby targeting progressive muscle weakness, myotonia, and systemic complications. It is the only gene therapy in development aiming to modify the disease’s underlying cause rather than just treating symptoms.
VX-670 is an investigational drug sponsored by Vertex Pharmaceuticals Incorporated, currently being studied in a Phase 2 open-label extension trial for myotonic dystrophy type I (DM1). This study is evaluating the long-term safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of VX-670 in adults. VX-670 is a phosphorodiamidate morpholino oligonucleotide (PMO) linked to a cyclic peptide, designed to enter muscle cells, target the CUG repeat RNA, and correct mis-splicing by releasing bound splicing factors, addressing the underlying cause of DM1.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Myotonic Dystrophy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for myotonic dystrophy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myotonic dystrophy collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share